At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Posaconazole +2 moredrug
Likely dose
Posaconazole 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)
In Brief
A Phase 2 clinical trial evaluating Posaconazole, Placebo for posaconazole, and 1 other intervention for Chagas Disease. Completed, enrolled 120 participants.
Detailed Summary
This is a study to compare the efficacy of oral posaconazole to placebo for the treatment of asymptomatic Chagas disease. The primary hypothesis of the study is that posaconazole 400 mg twice daily improves therapeutic response compared to placebo in participants with a diagnosis of asymptomatic chronic Chagas disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChagas Disease
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartJul 2011
Primary CompletionJul 2014
Study CompletionJan 2015
TodayJul 2026
First PostedJun 21, 2011
Enrollment StartJul 6, 2011
Primary CompletionJul 22, 2014
Study CompletionJan 12, 2015
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 15.0 years ago
Interventions
Posaconazoledrug
POS 40 mg/mL oral suspension
Placebo for posaconazoledrug
Placebo oral suspension
Benznidazoledrug
BNZ 100 mg oral tablet